Clinical Trial Update: Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and efficacy data for the investigational agent AGN208397 in macular edema associated with retinal vein occlusion, eva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• AGN208397

Snippet

Sponsor: Allergan | Conditions: Macular Edema, Retinal Vein Occlusion | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-29